Grant: Doctoral Research Award: Canada Graduate Scholarships
McGill University
$105,000.00
Investigating the Chi3l1-neutrophil axis in breast cancer progression
EF 2023-24
Résumé
Breast cancer is the most common type of cancer and a leading cause of death among women worldwide. Breast cancers progress in distinct step-wise fashion from benign to malignant tumors that can spread to other organs. With increased screening, early detection of benign breast lesions now represents 20% of new breast cancer cases. It is estimated that only half of those would advance to malignant tumors. However, because there are no clinical or genetic markers that can predict progression, all patients are subjected to surgery or aggressive therapies. This has led to significant over-treatment and exposing patients to serious side effects. Understanding the drivers of malignant transition will improve personalized treatment of early breast cancer by unveiling new ways to identify patients that would benefit from treatment.
Our lab recently identified that a protein called Chitinase-3 like 1 (Chi3l1) recruits neutrophils, a tumor-supporting immune cell, during breast cancer progression. We hypothesize that Chi3l1 and neutrophils play a critical role during malignant transition of breast cancers. In this project, we will evaluate Chi3l1 and neutrophil levels in early breast cancer patient samples and assess whether they are associated with increased risk of disease progression. Moreover, preclinical therapeutic experiments will investigate whether inhibiting Chi3l1 or neutrophils can prevent breast cancer advancement. Our findings will shed light on the potential for Chi3l1 and neutrophils as predictors and targetable vulnerabilities that can be exploited to inhibit breast cancer progression.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
497113
Name
Taifour Tarek
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Investigating the Chi3l1-neutrophil axis in breast cancer progression
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Ductal Carcinoma In Situ; Genetically Engineered Mouse Models; Myoepithelium Disruption; Neutrophils; Oncology
Abstract
Breast cancer is the most common type of cancer and a leading cause of death among women worldwide. Breast cancers progress in distinct step-wise fashion from benign to malignant tumors that can spread to other organs. With increased screening, early detection of benign breast lesions now represents 20% of new breast cancer cases. It is estimated that only half of those would advance to malignant tumors. However, because there are no clinical or genetic markers that can predict progression, all patients are subjected to surgery or aggressive therapies. This has led to significant over-treatment and exposing patients to serious side effects. Understanding the drivers of malignant transition will improve personalized treatment of early breast cancer by unveiling new ways to identify patients that would benefit from treatment.
Our lab recently identified that a protein called Chitinase-3 like 1 (Chi3l1) recruits neutrophils, a tumor-supporting immune cell, during breast cancer progression. We hypothesize that Chi3l1 and neutrophils play a critical role during malignant transition of breast cancers. In this project, we will evaluate Chi3l1 and neutrophil levels in early breast cancer patient samples and assess whether they are associated with increased risk of disease progression. Moreover, preclinical therapeutic experiments will investigate whether inhibiting Chi3l1 or neutrophils can prevent breast cancer advancement. Our findings will shed light on the potential for Chi3l1 and neutrophils as predictors and targetable vulnerabilities that can be exploited to inhibit breast cancer progression.
Competitiondate
202311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Taifour, Tarek
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~